146 related articles for article (PubMed ID: 31635559)
1. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Sato T; Nakamura H; Fujieda Y; Ohnishi N; Abe N; Kono M; Kato M; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
Lupus; 2019 Nov; 28(13):1577-1582. PubMed ID: 31635559
[TBL] [Abstract][Full Text] [Related]
2. Comparing APLS and oranges: caution with the use of direct-acting oral anticoagulants (DOACs) instead of warfarin in the treatment of antiphospholipid syndrome (APLS).
Benger M; Vink J; Snell LB; Breen K
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30940667
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Noel N; Dutasta F; Costedoat-Chalumeau N; Bienvenu B; Mariette X; Geffray L; Sene D; Chaidi RB; Michot JM; Fain O; Darnige L; Ankri A; Cacoub P; Piette JC; Saadoun D
Autoimmun Rev; 2015 Aug; 14(8):680-5. PubMed ID: 25864630
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
Seredavkina NV; Reshetnyak TM; Satybaldyeva MA; Kashnikova LN; Temnikova TA; Nasonov EL
Ter Arkh; 2019 May; 91(5):19-25. PubMed ID: 32598672
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: additional information.
Letic M
Lupus; 2020 May; 29(6):659-660. PubMed ID: 32151179
[No Abstract] [Full Text] [Related]
8. Low recurrent thrombosis rates in single positive antiphospholipid syndrome regardless of type of anticoagulation.
Bakow BR; Yanek L; Crowther MA; Chaturvedi S
Thromb Res; 2024 May; 237():88-93. PubMed ID: 38569453
[TBL] [Abstract][Full Text] [Related]
9. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
Sugie M; Iizuka N; Shimizu Y; Ichikawa H
Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
[TBL] [Abstract][Full Text] [Related]
10. The management of thrombosis in the antiphospholipid-antibody syndrome.
Khamashta MA; Cuadrado MJ; Mujic F; Taub NA; Hunt BJ; Hughes GR
N Engl J Med; 1995 Apr; 332(15):993-7. PubMed ID: 7885428
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome.
Ohnishi N; Fujieda Y; Hisada R; Nakamura H; Kato M; Oku K; Bohgaki T; Amengual O; Yasuda S; Atsumi T
Rheumatology (Oxford); 2019 Jun; 58(6):969-974. PubMed ID: 30508199
[TBL] [Abstract][Full Text] [Related]
13. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.
Ruiz-Irastorza G; Khamashta MA; Hunt BJ; Escudero A; Cuadrado MJ; Hughes GR
Arch Intern Med; 2002 May; 162(10):1164-9. PubMed ID: 12020188
[TBL] [Abstract][Full Text] [Related]
14. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
[TBL] [Abstract][Full Text] [Related]
15. Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban.
Htut TW; Milne D; Khan MM; Watson HG
Int J Lab Hematol; 2021 Oct; 43(5):e252-e253. PubMed ID: 33470532
[No Abstract] [Full Text] [Related]
16. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome. Dr. Hannah Cohen about the results of the RAPS trial (Lancet Haematol 2016; 3: e426-36).
Rheumatology (Oxford); 2017 Sep; 56(9):e23. PubMed ID: 28859331
[No Abstract] [Full Text] [Related]
17. Direct-acting oral anticoagulants in antiphospholipid syndrome: A systematic review.
Girón-Ortega JA; Girón-González JA
Med Clin (Barc); 2023 Jul; 161(2):65-77. PubMed ID: 37105842
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Rosove MH; Brewer PM
Ann Intern Med; 1992 Aug; 117(4):303-8. PubMed ID: 1637025
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Miao B; Alberts MJ; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2019 Oct; 48(3):366-372. PubMed ID: 31228038
[TBL] [Abstract][Full Text] [Related]
20. Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome.
Sciascia S; Lopez-Pedrera C; Cecchi I; Pecoraro C; Roccatello D; Cuadrado MJ
Rheumatology (Oxford); 2016 Oct; 55(10):1726-35. PubMed ID: 26843482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
